A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies

Blood

Volumn 119, Issue 3, 2012, Pages 884-893

  Allen, Kristi L ^a   Fonseca, Fabio V ^a   Betapudi, Venkaiah ^a   Willard, Belinda ^a   Zhang, Jainwei ^b   McCrae, Keith R ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CALRETICULIN; LIPOCORTIN 2; NUCLEOLIN; TOLL LIKE RECEPTOR 4;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84862909113     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-344671     Document Type: Article

References (50)

1. Rand JH. The antiphospholipid syndrome. Ann Rev Med. 2003;54:409-424. (Pubitemid 37386404)
2. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498-1509.
3. Pierangeli SS, Chen PP, Raschi E, et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost. 2008;34(3):236-250.
4. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68:1428-1432.
5. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87(11):4120-4125.
6. Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA. A phospholipid-beta2-glycoprotein complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus. 1992;1(2):75-81.
7. de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7(11):1767-1773.
8. Arad A, Proulle V, Furie RA, Furie BC, Furie B. Beta2 glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood. 2011;117(24):3453-3459.
9. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007; 109(2):422-429.
10. Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995;96(5): 2211-2219.
11. Zhang J, McCrae KR. Annexin II mediates endothelial cell activation by antiphospholipid/antibeta2-glycoprotein I antibodies. Blood. 2005; 105(5):1964-1969. (Pubitemid 40731779)
12. Del Papa N, Guidala L, Sala A, et al. Endothelial cells as targets for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997;40(3):551-561.
13. Cines DB, Pollak EA, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91(10):3527-3561. (Pubitemid 28225719)
14. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood. 2009;114(14): 3074-3083.
15. Pierangeli SS, Barker JH, Stikovac D, et al. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost. 1994;71(5):670-674.
16. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and P-Selectin. Circ Res. 2001;88(2):245-250. (Pubitemid 32147315)
17. Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS. E-Selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost. 2003;1(4):843-848.
18. Ma K, Simantov R, Zhang J-C, Silverstein R, Hajjar KA, McCrae KR. High affinity binding of beta2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem. 2000; 275(20):15541-15548. (Pubitemid 30337288)
19. Raschi E, Testoni D, Dosisio D, et al. Role of the MyD88 transduction signaling pathway in endothelial cell activation by antiphospholipid antibodies. Blood. 2003;101(9):3495-3500. (Pubitemid 36857933)
20. Monestier M, Kandiah DA, Kouts S, et al. Monoclonal antibodies from NZW x BXSB F1 mice to beta2 glycoprotein I and cardiolipin. Species specificity and charge-dependent binding. J Immunol. 1996;156(7):2631-2641.
21. Ramesh S, Morrell CN, Tarango C, et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via beta2GPI and apoER2. J Clin Invest. 2011;121(1):120-131.
22. Allen KL, Hamik A, Jain MK, McCrae KR. Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors. Blood. 2011;117(23):6383-6391.
23. Alard JE, Gaillard F, Daridon C, Shoenfeld Y, Jamin C, Youinou P. TLR2 is one of the endothelial receptors for beta 2-glycoprotein I. J Immunol. 2010;185(3):1550-1557.
24. Satta N, Kruithof EK, Fickentscher C, et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. Blood. 2011;117(20):5523-5531.
25. de Groot PG, Derksen RH, Urbanus RT. The role of LRP8 (ApoER2′) in the pathophysiology of the antiphospholipid syndrome. Lupus. 2010;19(4): 389-393.
26. Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT, et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood. 2011;117(4):1408-1414.
27. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol. 2003; 163(4):871-878. (Pubitemid 37517893)
28. Shi H, Huang Y, Zhou H, et al. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood. 2007;110(8): 2899-2906. (Pubitemid 350006943)
29. Huddleson JP, Ahmad N, Lingrel JB. Up-regulation of the KLF2 transcription factor by fluid shear stress requires nucleolin. J Biol Chem. 2006;281(22): 15121-15128. (Pubitemid 43855101)
30. Tarr JM, Winyard PG, Ryan B, et al. Extracellular calreticulin is present in the joints of patients with rheumatoid arthritis and inhibits FasL (CD95L)-mediated apoptosis of T cells. Arthritis Rheum. 2010;62(10):2919-2929.
31. Ghiran I, Klickstein LB, Nicholson-Weller A. Calreticulin is at the surface of circulating neutrophils and uses CD59 as an adaptor molecule. J Biol Chem. 2003;278(23):21024-21031. (Pubitemid 36806413)
32. Montiel-Manzano G, Romay-Penabad Z, Papalardo de ME, et al. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann N Y Acad Sci. 2007;1108:540-553. (Pubitemid 47528768)
33. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol. 2000;20:E83-E88.
34. MacLeod TJ, Kwon M, Filipenko NR, Waisman DA. Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits. J Biol Chem. 2003;278: 25577-25584.
35. Deora AB, Kreitzer G, Jacovina AT, Hajjar KA. An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J Biol Chem. 2004;279(42):43411-43418. (Pubitemid 39390640)
36. Kennedy MN, Mullen GE, Leifer CA, et al. A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J Biol Chem. 2004;279(33):34698-34704. (Pubitemid 39318100)
37. Visintin A, Mazzoni A, Spitzer JA, Segal DM. Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci U S A. 2001;98(21):12156-12161. (Pubitemid 32959843)
38. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science. 2010; 327(5961):46-50.
39. 2-Glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum. 2007;56(8):2687-2697.
40. He KL, Sui G, Xiong H, et al. Feedback regulation of endothelial cell surface plasmin generation by PKC-dependent phosphorylation of annexin A2. J Biol Chem. 2011;286(17):15428-15439.
41. Nishiya T, Kajita E, Miwa S. Ligand-independent oligomerization of TLR4 regulated by a short hydrophobic region adjacent to the transmembrane domain. Biochem Biophys Res Commun. 2006; 341(4):1128-1134. (Pubitemid 43221782)
42. Panter G, Jerala R. The ectodomain of the Toll-like receptor 4 prevents constitutive receptor activation. J Biol Chem. 2011;286(26):23334-23344.
43. Youn HS, Lee JK, Choi YJ, et al. Cinnamaldehyde suppresses toll-like receptor 4 activation mediated through the inhibition of receptor oligomerization. Biochem Pharmacol. 2008;75(2): 494-502.
44. Cesarman-Maus G, Ríos-Luna N, Deora AB, et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood. 2006;107(11):4375-4382. (Pubitemid 43801363)
45. Nagyoszi P, Wilhelm I, Farkas AE, et al. Expression and regulation of toll-like receptors in cerebral endothelial cells. Neurochem Int. 2010;57(5): 556-564.
46. Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, De Groot PG. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem. 2003;278(36):33831-33838. (Pubitemid 37553217)
47. Goicoechea S, Pallero MA, Eggleton P, Michalak M, Murphy-Ullrich JE. The anti-adhesive activity of thrombospondin is mediated by the N-terminal domain of cell surface calreticulin. J Biol Chem. 2002; 277(40):37219-37228.
48. Feng X, Tonnesen MG, Peerschke EI, Ghebrehiwet B. Cooperation of C1q receptors and integrins in C1q-mediated endothelial cell adhesion and spreading. J Immunol. 2002; 168(5):2441-2448. (Pubitemid 34171848)
49. Laird MH, Rhee SH, Perkins DJ, et al. TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol. 2009;85(6):966-977.
50. Ortona E, Capozzi A, Colasanti T, et al. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood. 2010; 116(16):2960-2967.